• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

初始肝切除时肿瘤负担对再次手术切除/射频消融后复发-死亡生存的影响:一项回顾性研究。

The impact of tumor burden at the initial hepatectomy on the recurrence-to-death survival after repeat surgical resection/radiofrequency ablation: a retrospective study.

机构信息

Department of Liver Surgery & Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.

出版信息

BMC Surg. 2022 May 18;22(1):193. doi: 10.1186/s12893-022-01643-7.

DOI:10.1186/s12893-022-01643-7
PMID:35585534
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9118788/
Abstract

BACKGROUND

Previous studies have reported the surgical resection (SR) and radiofrequency ablation (RFA) could achieve comparable recurrence-to-death survival (RTDS). However, the impact of primary tumor burden on RTDS of patients with recurrent hepatocellular carcinoma (HCC) following SR or RFA has not been clarified.

METHODS

From January 2009 to March 2015, 171 patients who underwent initial hepatectomy and second curative treatments in West China Hospital were retrospectively analyzed. Survival analysis was performed by the Kaplan-Meier method. Risk factors were identified using the Cox proportional hazard model.

RESULTS

At initial hepatectomy, 96 patients (56.1%) were diagnosed with HCC within the Milan criteria (MC), and 75 patients (43.9%) were HCC beyond the MC. The clinicopathological features and re-treatment methods of recurrent HCC were similar between patients with primary HCC within or beyond the MC. Patients with primary HCC within the MC had longer recurrence time (31.4 ± 24.2 months vs. 20.2 ± 16 months, P < 0.001). The 1- and 3- year RTDS within and beyond the MC group were 88.8%, 57.6% and 79.0%, 46.3%, respectively (P = 0.093). In multivariate analysis, the recurrence time, tumor size and AFP > 400 ng/mL at the time of recurrence were associated with RTDS.

CONCLUSIONS

The primary tumor burden had no impact on RTDS, but had an impact on recurrence time. The recurrence time had an impact on RTDS and might be a good index to reflect the biology of recurrent HCC.

摘要

背景

先前的研究报告称,手术切除 (SR) 和射频消融 (RFA) 可实现可比的复发至死亡生存 (RTDS)。然而,原发性肿瘤负担对 SR 或 RFA 后复发性肝细胞癌 (HCC)患者的 RTDS 的影响尚未阐明。

方法

从 2009 年 1 月至 2015 年 3 月,回顾性分析了在华西医院接受初始肝切除术和第二次治愈性治疗的 171 例患者。采用 Kaplan-Meier 法进行生存分析。使用 Cox 比例风险模型确定危险因素。

结果

在初始肝切除时,96 例患者 (56.1%) 被诊断为米兰标准 (MC) 内的 HCC,75 例患者 (43.9%) 为 MC 外的 HCC。MC 内或 MC 外原发性 HCC 患者的复发 HCC 的临床病理特征和再治疗方法相似。MC 内原发性 HCC 患者的复发时间更长 (31.4±24.2 个月比 20.2±16 个月,P<0.001)。MC 内和 MC 外组的 1 年和 3 年 RTDS 分别为 88.8%、57.6%和 79.0%、46.3%(P=0.093)。多因素分析显示,复发时间、肿瘤大小和复发时 AFP>400ng/mL 与 RTDS 相关。

结论

原发性肿瘤负担对 RTDS 没有影响,但对复发时间有影响。复发时间对 RTDS 有影响,可能是反映复发性 HCC 生物学特性的一个良好指标。

相似文献

1
The impact of tumor burden at the initial hepatectomy on the recurrence-to-death survival after repeat surgical resection/radiofrequency ablation: a retrospective study.初始肝切除时肿瘤负担对再次手术切除/射频消融后复发-死亡生存的影响:一项回顾性研究。
BMC Surg. 2022 May 18;22(1):193. doi: 10.1186/s12893-022-01643-7.
2
Radiofrequency ablation versus repeat resection for recurrent hepatocellular carcinoma (≤ 5 cm) after initial curative resection.射频消融与再次切除治疗初始根治性切除后复发的≤5cm 肝细胞癌。
Eur Radiol. 2020 Nov;30(11):6357-6368. doi: 10.1007/s00330-020-06990-8. Epub 2020 Jun 11.
3
The 10-year Survival Analysis of Radiofrequency Ablation for Solitary Hepatocellular Carcinoma 5 cm or Smaller: Primary versus Recurrent HCC.单发 5cm 或以下肝癌射频消融治疗的 10 年生存分析:原发性与复发性 HCC。
Radiology. 2021 Aug;300(2):458-469. doi: 10.1148/radiol.2021200153. Epub 2021 May 18.
4
Radiofrequency ablation surgical resection in elderly patients with hepatocellular carcinoma in Milan criteria.射频消融术与手术切除治疗米兰标准老年肝细胞肝癌的疗效比较
World J Gastroenterol. 2021 May 14;27(18):2205-2218. doi: 10.3748/wjg.v27.i18.2205.
5
No-touch multibipolar radiofrequency ablation vs. surgical resection for solitary hepatocellular carcinoma ranging from 2 to 5 cm.无接触式多点射频消融与手术切除治疗 2-5cm 单发肝细胞癌的比较。
J Hepatol. 2018 Jun;68(6):1172-1180. doi: 10.1016/j.jhep.2018.01.014. Epub 2018 Feb 2.
6
Clinical outcomes of surgical resection versus radiofrequency ablation in very-early-stage hepatocellular carcinoma: a propensity score matching analysis.非常早期肝细胞癌手术切除与射频消融治疗的临床结局:倾向评分匹配分析。
BMC Gastroenterol. 2021 Nov 8;21(1):418. doi: 10.1186/s12876-021-01995-z.
7
A prognostic model and treatment strategy for intrahepatic recurrence of hepatocellular carcinoma after curative resection.根治性切除术后肝细胞癌肝内复发的预测模型和治疗策略。
World J Surg. 2011 Jan;35(1):170-7. doi: 10.1007/s00268-010-0794-8.
8
Treatment effect of radiofrequency ablation versus liver transplantation and surgical resection for hepatocellular carcinoma within Milan criteria: a population-based study.射频消融与肝移植和手术切除治疗米兰标准内肝细胞癌的疗效比较:一项基于人群的研究。
Eur Radiol. 2021 Jul;31(7):5379-5389. doi: 10.1007/s00330-020-07551-9. Epub 2021 Jan 6.
9
Predicting Hepatocellular Carcinoma Recurrence Beyond Milan Criteria After Liver Resection for Solitary Hepatocellular Carcinoma.预测米兰标准以外的单发肝细胞癌肝切除后肝细胞癌复发。
J Gastrointest Surg. 2020 Oct;24(10):2219-2227. doi: 10.1007/s11605-019-04363-1. Epub 2019 Sep 3.
10
Survival analysis of re-resection versus radiofrequency ablation for intrahepatic recurrence after hepatectomy for hepatocellular carcinoma.肝癌切除术后肝内复发再切除与射频消融的生存分析。
World J Surg. 2012 Jan;36(1):151-6. doi: 10.1007/s00268-011-1323-0.

本文引用的文献

1
Comment on pediatric living donor liver transplantation decade progress in Shanghai: Characteristics and risks factors of mortality.上海儿童活体肝移植十年进展述评:死亡特征及危险因素
World J Gastroenterol. 2020 Aug 14;26(30):4564-4566. doi: 10.3748/wjg.v26.i30.4564.
2
Comment on experience with LDLT in patients with hepatocellular carcinoma and portal vein tumor thrombosis postdownstaging.关于肝细胞癌合并门静脉癌栓降期后活体肝移植患者的经验评论
Int J Surg Case Rep. 2020;74:36-37. doi: 10.1016/j.ijscr.2020.07.057. Epub 2020 Jul 28.
3
Liver Transplantation for Hepatocellular Carcinoma: Malatya Experience and Proposals for Expanded Criteria.
肝移植治疗肝细胞癌:马拉蒂亚经验及扩大标准的建议。
J Gastrointest Cancer. 2020 Sep;51(3):998-1005. doi: 10.1007/s12029-020-00424-w.
4
Long-term Effects of Repeat Hepatectomy vs Percutaneous Radiofrequency Ablation Among Patients With Recurrent Hepatocellular Carcinoma: A Randomized Clinical Trial.重复肝切除术与经皮射频消融治疗复发性肝细胞癌的长期疗效比较:一项随机临床试验。
JAMA Oncol. 2020 Feb 1;6(2):255-263. doi: 10.1001/jamaoncol.2019.4477.
5
Comparison of repeated surgical resection and radiofrequency ablation for small recurrent hepatocellular carcinoma after primary resection.原发性切除术后小复发性肝细胞癌的重复手术切除与射频消融的比较
Oncotarget. 2017 Oct 7;8(61):104571-104581. doi: 10.18632/oncotarget.21604. eCollection 2017 Nov 28.
6
The STROCSS statement: Strengthening the Reporting of Cohort Studies in Surgery.STROCSS 声明:加强外科学队列研究报告。
Int J Surg. 2017 Oct;46:198-202. doi: 10.1016/j.ijsu.2017.08.586. Epub 2017 Sep 7.
7
Treatment for intrahepatic recurrence after curative resection of hepatocellular carcinoma: Salvage liver transplantation or re-resection/radiofrequency ablation? A Retrospective Cohort Study.根治性切除术后肝内复发肝细胞癌的治疗:挽救性肝移植或再次切除/射频消融?一项回顾性队列研究。
Int J Surg. 2017 Oct;46:178-185. doi: 10.1016/j.ijsu.2017.09.001. Epub 2017 Sep 7.
8
A systematic review and meta-analysis comparing the prognosis of multicentric occurrence and vs. intrahepatic metastasis in patients with recurrent hepatocellular carcinoma after hepatectomy.一项比较肝切除术后复发性肝细胞癌患者多中心发生与肝内转移预后的系统评价和荟萃分析。
HPB (Oxford). 2017 Oct;19(10):835-842. doi: 10.1016/j.hpb.2017.06.002. Epub 2017 Jul 19.
9
Meta-analysis of determinants of survival following treatment of recurrent hepatocellular carcinoma.复发性肝细胞癌治疗后生存影响因素的荟萃分析
Br J Surg. 2017 Oct;104(11):1433-1442. doi: 10.1002/bjs.10597. Epub 2017 Jun 19.
10
Salvage hepatectomy for local recurrence of hepatocellular carcinomas offers survival comparable to that of matched patients who undergo primary hepatectomies.肝细胞癌局部复发后行挽救性肝切除术,其生存率与接受初次肝切除术的匹配患者相当。
Eur J Surg Oncol. 2017 Jun;43(6):1076-1082. doi: 10.1016/j.ejso.2017.03.021. Epub 2017 Apr 19.